[Pubmed] Case report: Efgartigimod is a novel therapeutic option for ocular myasthenia gravis: a report of 2 cases
Posté : 28 janv. 2025 12:00
Front Immunol. 2025 Jan 13;15:1497398. doi: 10.3389/fimmu.2024.1497398. eCollection 2024.
ABSTRACT
INTRODUCTION: Efgartigimod has been approved for the treatment of acetylcholine receptor antibodies-positive generalized myasthenia gravis (AChR-Ab+gMG), but its efficacy in patients with ocular myasthenia gravis (OMG) is not known.
CASE PRESENTATION: We describe 2 cases of patients with AChR-Ab+ OMG who showed unfavorable responses to corticosteroids and tacrolimus. Within 2 weeks of initiating efgartigimod, both patients showed rapid improvement and minimal symptom expression was achieved in weeks 3 to 4, which was maintained up to week 12.
CONCLUSION: The 2 cases described herein provide preliminary evidence for the effectiveness of efgartigimod for the treatment of OMG for patients who do not respond or are intolerant to conventional medications. Large-scale studies are needed to confirm these findings.
PMID:39872535 | PMC:PMC11769809 | DOI:10.3389/fimmu.2024.1497398
Source: https://pubmed.ncbi.nlm.nih.gov/3987253 ... t9+e462414